Novartis pays big fine for bribing doctors in the US
Swiss pharma company Novartis will pay $729 million (CHF688 million) to US authorities in an out-of-court settlement over various charges, including that the company bribed doctors to use its drugs.
This content was published on
2 minutes
Keystone-SDA/dos
Audrey Strauss, the acting Manhattan US Attorney, said the firm had paid out for “speaking fees, exorbitant meals, and top-shelf alcohol that were nothing more than bribes to get doctors across the country to prescribe Novartis’s drugs.”
Essentially, Novartis admitted to having organised thousands of lavish conferences and events ostensibly aimed at “further education”. Guest speakers were paid large amounts to attend.
In return, the doctors were incentivised to prescribe Novartis products, such as drugs for high blood pressure and diabetes, which were then reimbursed by state health authorities.
“Not only did Novartis incentivise doctors to host these speaking events, reps bribed the doctors to write more prescriptions of the company’s drugs to give Novartis an advantage over competitors within their field,” said William F Sweeney Jr, head of New York’s FBI office.
“Greed replaced the responsibility the public expects from those who practice medicine.”
As part of the agreement with US authorities, Novartis has signed a five-year code of good conduct. The Basel-based firm also said on Thursday that it was revising its methods of providing medical training, notably by planning more online webinars.
In a statement, Novartis CEO Vas Narasimhan said that the company had already changed (the charges in question were raised by a whistle-blower in 2011) and that it had “new leadership, a stronger culture, and a more comprehensive commitment to ethics”.
“With these agreements we mark an important milestone on our journey to build trust with society as we continue re-imagining medicine to improve and extend lives all around the world,” Narasimhan said.
A week ago Novartis and two of its subsidiaries admitted to further bribery schemes involving dealings in Vietnam and Greece, and agreed to pay some $347 million to settle US investigations.
As of Thursday, the stock market has not reacted particularly strongly: the Novartis share price dropped 0.8%, around the same as its competitor Roche.
Popular Stories
More
Foreign affairs
Go to war or stay put? Ukrainian men in Switzerland face fresh dilemmas
Is reforming the Swiss pension system still possible, and if so, how?
Solutions still need to be found to meet the challenge of an ageing population and to improve the pensions of low-paid workers, the majority of whom are women.
Swiss to reduce administrative burden on farms from 2026
This content was published on
From 2026, the number of inspections of farms is to be reduced, without any loss of quality, said economics minister Guy Parmelin.
Swiss insurance boss proposes Singapore-style healthcare system
This content was published on
CEO of Swiss health insurer Sanitas has said that healthcare costs could be reduced if Switzerland were to follow the Singapore model.
Swiss minister talks crime and security in visit to the Netherlands
This content was published on
Swiss justice minister Beat Jans spent two days in the Netherlands discussing security, police cooperation and justice with international bodies.
Study finds more heavy metal detected in Swiss grassland
This content was published on
Copper and zinc can be expected to accumulate in the soil, particularly if farmyard manure is used for several years and is greater than the amount of nutrients absorbed by the grass. This was announced by the Federal Office for the Environment (FOEN) on Friday. The findings are based on the results of the seventh National Soil Monitoring of Switzerland (Nabo).
Lilo Baur wins Swiss Grand Prix for performing arts
This content was published on
The Swiss actress and theatre director Lilo Baur has received this year's Swiss Grand Prix for Performing Arts, also known as the Hans Reinhart Ring.
Court rules al-Qaeda supporter can stay in Switzerland
This content was published on
A Kurdish supporter of the Islamist terrorist network al-Qaeda can stay in Switzerland, the Federal Administrative Court has ruled. It has withdrawn the annulment of the man’s provisional admission.
This content was published on
The Office of the Attorney General of Switzerland (OAG) has closed criminal proceedings relating to the Swiss owners affected by the Volkswagen “Dieselgate” emissions scandal.
This content was published on
The employment outlook in Switzerland will remain stable towards the end of 2024, according to the KOF Swiss Economic Institute at ETH Zurich.
Swiss woman accuses Donald Trump of sexual assault
This content was published on
A former Miss Switzerland candidate has accused Donald Trump of sexually assaulting her in New York in 1993. The US Republican candidate’s campaign team has denied the accusations.
If you want to start a conversation about a topic raised in this article or want to report factual errors, email us at english@swissinfo.ch.
Read more
More
Novartis CEO warns that data on Covid-19 drugs is missing
This content was published on
Potential pharmaceutical solutions to combat Covid-19 must have strong clinical data to back their efficacy, according to Novartis boss Vasant Narasimhan.
US Senate asks Novartis to shed light on data manipulation allegations
This content was published on
The Swiss pharmaceutical firm Novartis has been asked to provide details regarding possible data inaccuracies for its human gene therapy Zolgensma.
Swiss pharma giants swallow up start-ups in push for next big gene therapy
This content was published on
Swiss drug makers are increasingly relying on buying science rather than doing it themselves in the search for the next big medical breakthrough.
You can find an overview of ongoing debates with our journalists here . Please join us!
If you want to start a conversation about a topic raised in this article or want to report factual errors, email us at english@swissinfo.ch.